PolyPid (NASDAQ:PYPD) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research report sent to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $14.00 price target on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.

PolyPid Stock Up 2.9 %

NASDAQ PYPD opened at $4.94 on Wednesday. The company has a debt-to-equity ratio of 2.17, a current ratio of 0.83 and a quick ratio of 0.83. PolyPid has a 1-year low of $3.57 and a 1-year high of $13.23. The business’s fifty day moving average price is $4.95 and its 200-day moving average price is $5.02.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, February 14th. The company reported ($3.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.17) by ($1.80). As a group, research analysts anticipate that PolyPid will post -3.72 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. acquired a new position in PolyPid Ltd. (NASDAQ:PYPD) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid makes up 1.8% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 20th largest position. Rosalind Advisors Inc. owned 8.67% of PolyPid at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.